TLDR: Strive Health, a leader in value-based kidney care, has successfully raised $550 million in a Series D funding round, including $300 million in equity and $250 million in debt financing. This substantial capital infusion, led by New Enterprise Associates (NEA) and Hercules Capital, will accelerate the company’s AI-driven approach to kidney disease management, aiming to expand its reach, enhance its technology, and deepen partnerships across the U.S. The company’s model has already demonstrated significant reductions in healthcare costs and hospitalizations.
Denver, CO – September 9, 2025 – Strive Health, a prominent national provider of value-based kidney care, announced today the successful close of a monumental $550 million Series D funding round. The financing package is composed of $300 million in Series D equity funding and an additional $250 million in debt financing, marking a significant milestone in the company’s mission to revolutionize kidney disease management. This latest capital raise brings Strive Health’s total funding to date to $700 million and boosts its valuation to an impressive $1.8 billion.
The equity round was spearheaded by New Enterprise Associates (NEA), with substantial participation from existing investors including CVS Health Ventures, CapitalG, Echo Health Ventures, Town Hall Ventures, and Redpoint. New institutional investors, including funds and accounts managed by affiliates of BlackRock, Inc., also joined the round. Hercules Capital led the debt financing component.
Strive Health’s innovative care model leverages advanced artificial intelligence (AI) and predictive analytics to identify patients with kidney disease at early stages, enabling timely interventions and preventative care. This approach supports patients throughout their entire kidney care journey, from chronic kidney disease (CKD) to end-stage kidney disease (ESRD), including dialysis and kidney transplant support. The company integrates seamlessly with local providers, forming a comprehensive care delivery system.
Chris Riopelle, co-founder and CEO of Strive Health, emphasized the company’s foundational vision: “When we founded Strive in 2018, the team set out to transform kidney care. The continued investments, combined with valued tech and healthcare strategics, is a clear signal that the Strive team is delivering on that mission. By transforming kidney care, we will ultimately make the healthcare system work better for patients and providers.” He further noted, “What we knew was that these patients could be helped prior to ending up on dialysis. We believed that using data analytics and machine learning and AI, we could identify patients sooner in the process, deploy a team… to engage that patient in a very focused way.”
The impact of Strive Health’s model has been substantial. The company reports a 20% reduction in total kidney care costs and a 41% decrease in hospitalizations for its patients. Furthermore, it boasts a 94% overall patient satisfaction rate. Since its inception in 2018, Strive has conducted over 1.3 million patient touchpoints.
Currently, Strive Health partners with more than 6,500 providers across all 50 U.S. states, serving over 145,000 individuals with kidney disease. The company manages nearly $5 billion in annual medical spending through partnerships with commercial health plans, Medicare Advantage payers, Medicare, health systems, and physicians, often through flexible value-based payment arrangements.
The newly secured funds will be strategically deployed to strengthen existing partnerships, expand its services to reach more patients and providers, and significantly enhance its AI-driven tools and analytics. Strive Health also plans to grow its multi-specialty offerings, potentially expanding into adjacent high-cost specialties such as congestive heart failure.
Mohamad Makhzoumi, co-CEO of NEA, highlighted the critical role of AI in healthcare: “We recognize that clinician-led healthcare solutions with meaningful scale are where AI implementations will have the most impact when it comes to improving outcomes for chronic disease management and preventive care — but those companies also happen to be exceedingly rare. NEA remains a proud supporter of Strive’s mission of deploying its innovative care model to slow the progression of kidney disease and we are excited at the potential for Strive’s impact to grow exponentially with this more than half a billion-dollar capital raise.”
Also Read:
- Twin Health Secures $53 Million Investment to Propel AI Digital Twin Platform for Metabolic Health
- Hello Patient Raises $22.5 Million Series A to Expand AI-Powered Healthcare Communications
This funding round underscores the growing investor confidence in value-based care models and the transformative potential of AI in addressing chronic diseases.
